Partnership / Collaboration · GCC · Announced 25 Oct 2026
Pinnacology Research & Development → Prognica Labs
Dubai-based Prognica Labs and India's Pinnacology signed a co-development and commercialisation partnership for a preclinical intranasal anxiety therapy, starting in India with possible GCC expansion. Terms were not disclosed.
Parties: Pinnacology Research & Development (India) → Prognica Labs (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- India as initial development focus; possible expansion to the GCC and other international markets, subject to regulatory approvals and clinical validation
- Therapeutic area
- CNS / Neurology
- Asset
- Intranasal anxiety therapy (preclinical)
- Announced
- 25 Oct 2026
Our analysis
Why this matters
Prognica Labs, a Dubai-headquartered, AI-driven life sciences company, has signed a strategic co-development and commercialisation partnership with India-based Pinnacology Research & Development for an investigational intranasal microemulsion therapy for anxiety. The candidate combines naturally derived phytochemicals, including flavan-3-ols, with aromatic resin extracts. It is preclinical: the partners report encouraging findings in preclinical behavioural studies, and the next work will assess drug exposure, nasal tolerability and onset of action. Financial terms were not disclosed.
India is the initial development focus. Expansion into the GCC and other international markets is possible, but only subject to regulatory approvals and clinical validation.
The full analysis is free to read with a work email on this page.
Source: BioSpectrum Asia